Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Individuals with autoimmune or immune mediated diseases (AID) are more susceptible to infections and often experience worse outcomes if infected, underscoring the importance of vaccination. However, it remains unclear whether vaccine effectiveness (VE) differs between persons with and without AID. Our aim was to compare the effectiveness of influenza and herpes zoster vaccines in both groups, where the AID group consists of individuals with either multiple sclerosis (MS), chronic inflammatory bowel disease (IBD) or chronic inflammatory rheumatic disorders (CIRD). METHODS: We emulated five target trials using claims data from a large German health insurance provider: one for herpes zoster and four for influenza across different seasons. We used 1:1 balanced risk set matching and Cox proportional hazards models with interaction terms between vaccination status and AID status to estimate VE and differences in VE across groups. RESULTS: For the herpes zoster trial, 169,054 vaccinated individuals were matched to the same number of controls, including 10,994 AID individuals per group. Herpes zoster VE was 68.73 (95% CI 55.75-77.91) in the AID group and 60.30 (55.59-64.52) in the non-AID group (VE ratio: 1.14, 95% CI 0.93-1.30). Across four influenza seasons (2015/2016-2018/2019) between 1403,342 and 1713,064 individuals were included, including between 56,662 and 78,320 AID individuals. Influenza VE varied by outcome, season, and assumptions, but VE ratios remained near one in most analyses (VE ratios: -0.92-3.77), with all CIs including one. CONCLUSIONS: There was no evidence that VE differs meaningfully between individuals with and without AID, conditional on the included confounders. Both vaccines were similarly effective across groups, suggesting that VE is not reduced in MS, IBD, or CIRD patients. Further research is necessary to validate these findings for other AID and infections.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases
- Date Crossref
- 01/08/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University Hospitals of the Ruhr-University of Bochum pays non établi dans la noticeÉtablissement de santé
-
Ruhr University Bochum Department of Medical Informatics pays non établi dans la noticeUniversité ou école supérieure
-
University of Cologne pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Cologne PMV Research Group pays non établi dans la noticeÉtablissement de santé
-
Zimmer Biomet (Germany) pays non établi dans la noticeEntreprise
-
St. Josef-Hospital pays non établi dans la noticeÉtablissement de santé
-
Katholisches Klinikum Bochum pays non établi dans la noticeÉtablissement de santé
-
Rheumazentrum Ruhrgebiet pays non établi dans la noticeÉtablissement de santé
-
Universitätsklinik Marien Hospital Herne pays non établi dans la noticeÉtablissement de santé
-
Jena University Hospital Department of Internal Medicine IV (Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
BARMER GEK pays non établi dans la noticeÉtablissement de santé
-
Medical Faculty pays non établi dans la noticeUniversité ou école supérieure
University Hospitals of the Ruhr-University of Bochum, Department of Medical Informatics — Ruhr University Bochum et University of Cologne, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.